ÌÇÐÄvlog

In a phase III randomized, placebo-controlled, double-blind clinical trial, Beal and coauthors examine whether coenzyme Q10 could slow disease progression in early Parkinson disease. See also the editorial by Schapira and Patel.

Van Laere and colleagues evaluated the use of ¹⁸fluorodeoxyglucose (FDG)–positron-emission tomography (PET) as a marker of amyotrophic lateral sclerosis (ALS) pathology and investigated whether a specific metabolic signature is present in patients with C9orf72 mutations. Foerster and Feldman provided a related .

Hughes et al examine the association between measures of arterial stiffness and change in β-amyloid deposition over time. See also the editorial by King.

Ong et al conduct a population-level study investigating the relationship between epilepsy and several common autoimmune diseases.

Liew and colleagues aimed to determine whether plasmapheresis or intravenous immunoglobulin (IVIG) therapy is more effective as maintenance therapy in juvenile myasthenia gravis.

Singh et al investigate whether a diagnosis of chronic obstructive pulmonary disease (COPD) and duration of COPD are associated with an increased risk for incident mild cognitive impairment and its subtypes.

Breen and colleagues define the sleep and circadian phenotype of patients with early-stage Parkinson disease.

Monaco et al determine whether mononuclear cells in circulation from patients with multiple sclerosis (MS) treated with natalizumab harbor DNA of the JC virus.

Serra et al use functional magnetic resonance imaging to assess the potential relationship between personality traits/disorders and changes to functional connectivity within the default mode network in patients with myotonic dystrophy type 1 (DM1).

Popa et al clarify the neurophysiological features of myoclonus-dystonia and discuss whether myoclonus-dystonia due to ε-sarcoglycan deficiency differs from other primary dystonias.